J-Star Research, Inc.

02/08/2022

Dr. San Kiang, of , was on ’s recently. In this clip, he speaks about the advances in breaking down traditional barriers between and developments.

For more on how we’re breaking those barriers, visit https://zcu.io/l0Fa or contact us via email at cfpc.jstar@jstar-research.com or via phone at 1-(609) 860-1300.

02/01/2022

Happy ! We hope that the brings good health, prosperity, and happiness to you and your family.

07/28/2021

J-Star Research, Inc will be exhibiting at CPhI North America from August 10-12th at the Pennsylvania Convention Center in Philadelphia. Come visit us at booth 2243 - this is your opportunity to start re-connecting with your industry peers and boost your business for the year ahead!

Visit J-Star Research and Porton from August 10th to 12th at this year's CPhINorthAmerica event. Our team will be available to discuss your drug developme

06/09/2021

On Saturday, June 6, Porton and Tianjin University National Engineering Research Center of Industrial Crystallization Technology (CICT) announced a school-enterprise strategic cooperation to jointly advance CICT's resource investment, technology development, talent training, teaching, research, industry-university cooperation, and innovation.

On Saturday, June 6, Porton and Tianjin University National Engineering Research Center of Industrial Crystallization Technology (CICT) announced a school-enter

06/01/2021

May 25, 2002, Shanghai, China. Porton Pharma Solutions Ltd., one of the world’s leading CDMOs, today celebrated the groundbreaking of its new drug product GMP site. Construction of the facility began this month and will continue in phases until the scheduled completion in the third quarter of 2022.
Built to exacting FDA/EMA standards, the new site will include an OSD clinical supply workshop, an OSD small scale commercial workshop, a High-potent OSD workshop, and an Injection (solution, lyophilization) workshop (isolated).
With this new phase 1, multifunctional GMP site, Porton will also significantly expand its Solubility enhancement (HM, Spray drying) and Complex formulation capabilities and capacities (MUPS, OROS etc. ), marking an even greater improvement in the company's ability to meet all phases of client drug product manufacturing and supply needs.
About Porton Pharma Solutions Ltd
Founded in July 2005, Porton Pharma Solutions Ltd. (Stock abbreviation: Porton Share; Stock code: 300363) is a leading pharmaceutical CDMO (Contract Development Manufacture Organization) in China.

From its earliest stages of development, Porton has provided global pharmaceutical companies and new drug R&D (Research and Development) institutions with customized R&D.
For further details, visit Porton online:
http://www.portonpharma.com

May 25, 2002, Shanghai, China. Porton Pharma Solutions Ltd., one of the world’s leading CDMOs, today celebrated the groundbreaking of its new drug product GMP

05/26/2021

To augment our significant in-house NMR resources, which includes 4 NMR spectrometers and 3 full-time NMR spectroscopists, J-Star is installing a 5 mm Cryoprobe on our Varian 500 MHz NMR. By cooling the detection coil and the preamplifier to near absolute-zero temperature, this new capability will provide the following advantages in support of J-Star’s structural elucidation group:
- NMR background noise greatly improved
- sensitivity gain over a room-temperature probe of up to 4X
- data collection time reduction of 20X
- structural elucidation work on analytes as low as 0.1 mg
When coupled with J-Star’s existing mass-directed preparative HPLC purification system, high resolution mass spectrometry capabilities, and experienced scientific team, this uniquely positions J-Star as an industry leader in the ability to support low level (0.1%) impurity isolation and identification from:
- process intermediates
- processing product streams and waste streams
- crystallization mother liquors and supernatants
- active pharmaceutical ingredients (drug substance or drug product).

To augment our significant in-house NMR resources, which includes 4 NMR spectrometers and 3 full-time NMR spectroscopists, J-Star is installing a 5 mm Cryoprobe

05/18/2021

Live from 17-28 May 2021, CPhI Discover is online event providing pharmaceutical professionals a way to meet, discuss, partner, source and learn online. No need to travel. CPhI Discover brings the international pharma industry to you, on your laptop, or mobile, in your living room or home office!
J-Star will be exhibiting in the CPHI online marketplace through May 28 - the perfect opportunity to learn about our latest and most innovative solutions and services before anyone else! Please contact sales@jstar-research.com for more information.

Live from 17-28 May 2021, CPhI Discover is online event providing pharmaceutical professionals a way to meet, discuss, partner, source and learn online. No need

05/17/2021

As part of our 7-week collaboration with XtalPi in the 2nd Edition of Fundamentals of Solid Formulation (FSF2021) webinar series, CfPC is pleased to announce the 7th webinar in the series, “Crystallisation in Agrochemicals: The Good, the Bad, and the Unusual” with Adam Keates, PhD (May 19 from 11:00 AM – Noon EDT).
There is no registration fee to participate in this virtual event as we would like to remove any barrier for broadening the learning opportunities and engagement with scientists and researchers at this time.
You may register now at: https://register.gotowebinar.com/register/5019538174999541004
ABSTRACT
Crystallisation is a common technique to isolate and purify small organic molecules in the pharmaceutical and agrochemical industries, however, there are unique challenges related to the agrochemical industry, which will be presented. Crystallisation can also be undesired and may occur throughout a product's lifecycle, for example during formulation temperature storage, spray tank mixing and droplet drying. In some instances, crystallisation can be minimised by understanding the relative stability and transitions between solid-states, especially across hydrate/anhydrate boundaries. In agrochemicals there are a range of formulation types and the desired solid-state is driven by formulation stability which can result in complex mixtures of solid forms.
BIOGRAPHY
Adam Keates graduated with a PhD from the University of Southampton looking into inorganic framework structures with a strong focus on crystallography to obtain structure-properties relationships. Since graduating he joined the leading agrochemical company, Syngenta, within the Process Studies Group based in Jealott's hill looking at polymorph discovery for new active ingredients. In this role he is looking to find new ways to crystallise and predict polymorphs and understand the influence on formulation.

As part of our 7-week collaboration with XtalPi in the 2nd Edition of Fundamentals of Solid Formulation (FSF2021) webinar series, CfPC is pleased to announce th

05/11/2021

As part of our 7-week collaboration with XtalPi in the 2nd Edition of Fundamental of Solid Formulation (FSF2021) webinar series, CfPC is pleased to announce the 6th webinar in the series, "Application of 15N SSNMR to Differentiate and Quantify Different API Amorphous Phases in Complex Tablet Formulation" with Ales Medek, PhD (May 12 from 11:00 AM – Noon EDT).

As part of our 7-week collaboration with XtalPi in the 2nd Edition of Fundamental of Solid Formulation (FSF2021) webinar series, CfPC is pleased to announce the

04/29/2021

Direct compression (DC) process is the preferred method for tablet production because it is both simple and energy saving. However, only a minority of active pharmaceutical ingredients (APIs) can be made into tablets by using DC because of the powder properties of most APIs (low bulk density, low flowability, etc.). Hence, technologies that can improve these powder properties are essential for DC.

Direct compression (DC) process is the preferred method for tablet production because it is both simple and energy saving.

04/22/2021

Cranbury, NJ, April 21,2021. J-Star Research, a leading provider of services in complex organic synthesis and crystallization for a variety of pharmaceutical clients globally, is launching its 2nd annual Pharmaceutical Crystallization Summit through its CfPC (Center for Pharma Crystallization) with the assistance of XtalPi and BlazeMetrics.
This year’s Summit, coming this October 14 and 15, will gather top industrial and academic experts to discuss their work related to DS crystallization R&D and manufacturing with a special focus on:
Areas of opportunity identified by Enabling Technologies Consortium
- Crystal structure prediction
- Crystal shape prediction
- Solubility assessment
- Purification
- Analytical technologies
Areas of potential innovation identified by National Academies of Sciences, Engineering, and Medicine
- Co-processed APIs
- Process intensification
- Additive manufacturing
- Advanced process control & automation
- Modular systems
In compliance with the CDC and New Jersey Department of Health guidelines, we are happy to announce that this year’s summit will be proceeding as a hybrid (live and virtual) with the following sessions:
- Smarter Solid Form and Preformulation Studies
- Physical Property Based Crystallization Process Development
- Particle Engineering and DS-DP Co-Processing
- Panel Discussions and Poster Presentations
For more information, please visit the Summit website at: https://www.pharmaceuticalcrystallizationsummit.com/

Cranbury, NJ, April 21,2021. J-Star Research, a leading provider of services in complex organic synthesis and crystallization for a variety of pharmaceutical cl

04/21/2021

Research studies show that the majority of API candidates in the development pipeline have a BCS Class II rating, which means those APIs need a solubilization strategy to promote the bioavailability to improve their chance of clinical success.
One commercially validated technique to improve the solubility of poorly-soluble APIs is to prepare them as amorphous solid dispersions (ASD). J-star Research Inc. has spray drying (SD), hot melt extrusion (HME) and co-processing in house to establish ASD technique. This case study is focused on the preparation and evaluation of one model ASD produced at J-Star using Spry Drying.

Research studies show that the majority of API candidates in the development pipeline have a BCS Class II rating, which means those APIs need a solubilization strategy to promote the bioavailability to improve their chance of clinical success.